Cost is not the primary barrier keeping Americans from weight loss drugs, despite historically high list prices and inconsistent insurance coverage, according to a March 17 Axios-Ipsos poll.
The finding is based on survey responses from a nationally representative sample of 1,225 U.S. adults polled March 6-9.
Three takeaways:
1. Among those not interested in GLP-1s, just 16% cited cost as the main reason. The most commonly cited factor for not using the medications was preferring to manage weight through diet and exercise (51%), followed by concerns about side effects (38%).
2. Still, the data show GLP-1 use continues to increase. Eighteen percent of Americans reported that they or a family member or friend is using a weight loss drug, up from 12% a year ago. About 11% said they have personally used a GLP-1.
3. The finding comes amid heightened concerns over healthcare costs more broadly. Sixty-nine percent of respondents said they are worried about potential insurance cost increases in 2026, and 68% said a 10% rate hike would negatively impact their household finances.
See the full survey here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
